News Neuralink raises $650m to widen use of brain implants Brain-computer interface firm Neuralink has completed a $650m financing that it says will help to "bring our technology to more people."
News GRIN raises $140m for epilepsy drug, and other financings Our round-up of recent biotech financings includes rounds for GRIN Therapeutics, GlycoEra, Syndeio, Juvenescence, and Vima Therapeutics.
News Digital player Hinge Health rises sharply after NYSE debut In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO.
News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News Azafaros bags €132m for rare neuro-metabolic disorder drugs Azafaros is set to start phase 3 trials of its lead drug for a trio of rare lysosomal storage disorders, backed by €132m in new Series B financing.
News Despite US turmoil, Hinge Health pushes ahead with IPO Digital health firm Hinge has published a new prospectus for its IPO, shrugging off the weakness in US stock markets caused by Trump's tariffs.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
